Yes, the S1R seems to be fantastic in its broad therapeutic value. It looks like the patent listed all possible applications of 2-73. There will be many trials run for years and years. It looks like Anavex is already moving 2-73 straight into P3 trials, so that will speed things up. As revenue rolls in, paying for many trials will not be an issue.
Once 2-73 is approved for sale, it will be interesting to how many people taking 2-73 for some problem, report improvements in unrelated health problems they have.
Hopefully, you get a 3 fer the price of one!
News 
Market Data 
Discover 
